Atorvastatin Before Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Jan 2

PMID 38165842

Authors

Mariano Garcia-Campa

Ramiro Flores-Ramirez

Sabrina Rojo-Garza

Edgar Francisco Carrizales-Sepulveda

Diego Regalado-Ceballos

Raul Reyes-Araiza

Neri Alvarez-Villalobos

Rene Rodriguez-Gutierrez

Jose Ramon Azpiri-Lopez

Affiliations

Soon will be listed here.

Abstract

Atorvastatin is widely recommended for long-term secondary prevention in STEMI patients with no contraindication. Although high-dose atorvastatin has been shown to reduce important patient outcomes such as MACE, there is still doubt that high-dose atorvastatin could have the same protective effect in patients undergoing PCI in the short and long term. We searched the following electronic databases: Scopus, Web of Science, MEDLINE, EMBASE, and Cochrane Central considering studies that enrolled adult patients with a confirmed diagnosis of STEMI or NSTEMI undergoing PCI. The intervention must have been atorvastatin alone compared to a placebo, standard care, or a different atorvastatin dose. A total of (n = 11) studies were included in the quantitative analysis. Information on (N = 5,399) patients was available; 2,654 were assigned to receive high-dose atorvastatin therapy, and 2,745 comprised the control group. High-dose atorvastatin pre-loading significantly reduced MACE at one month of follow-up (RR: 0.78; 95% CI: 0.67-0.91; p = 0.014) in both STEMI and NSTEMI. All-cause mortality was reduced in patients with STEMI (RR: 0.28; 95% CI: 0.10-0.81; p = 0.029). The quality of the body of evidence was rated overall as moderate. Patients presenting with STEMI or NSTEMI benefit from high-dose atorvastatin pre-loading before PCI by reducing MACE at 30 days. The use of high-dose atorvastatin in STEMI patients reduced all-cause mortality. The beneficial effects of atorvastatin pre-loading are limited to 30 days post-PCI.

References

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

Berwanger O, Santucci E, de Barros E Silva P, de Andrade Jesuino I, Damiani L, Barbosa L . Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA. 2018; 319(13):1331-1340. PMC: 5876881. DOI: 10.1001/jama.2018.2444. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Kim J, Kim J, Choi D, Lee C, Lee S, Ko Y . Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010; 3(3):332-9. DOI: 10.1016/j.jcin.2009.11.021. View

Li Q, Zhao Y, Wang Z, Jiang H, Liu W, Cao B . Effects of First High-Dose Atorvastatin Loading in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Am J Ther. 2016; 25(3):e291-e298. DOI: 10.1097/MJT.0000000000000370. View

Liu H, Yang Y, Yang S, Luo J, Li H, Jing L . Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients: a randomized clinical study. Clin Ther. 2013; 35(3):261-72. DOI: 10.1016/j.clinthera.2013.01.009. View

Zhang D, Wang S, Guan Y, Wang L, Xie W, Li N . Effect of oral atorvastatin on CD4+CD25+ regulatory T cells, FoxP3 expression, and prognosis in patients with ST-segment elevated myocardial infarction before primary percutaneous coronary intervention. J Cardiovasc Pharmacol. 2011; 57(5):536-41. DOI: 10.1097/FJC.0b013e318211d016. View

Ma M, Bu L, Shi L, Guo R, Yang B, Cao H . Effect of loading dose of atorvastatin therapy prior to percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of six randomized controlled trials. Drug Des Devel Ther. 2019; 13:1233-1240. PMC: 6585398. DOI: 10.2147/DDDT.S196588. View

Borovac J, Leth-Olsen M, Kumric M, DAmario D, Schwarz K, Glavas D . Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials with GRADE qualification of available evidence. Eur J Clin Pharmacol. 2021; 78(1):111-126. DOI: 10.1007/s00228-021-03196-9. View

10.

Boden W, ORourke R, Teo K, Hartigan P, Maron D, Kostuk W . Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356(15):1503-16. DOI: 10.1056/NEJMoa070829. View

11.

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

12.

Pedersen T, Cater N, Faergeman O, Kastelein J, Olsson A, Tikkanen M . Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL].... Am J Cardiol. 2010; 106(3):354-9. DOI: 10.1016/j.amjcard.2010.03.033. View

13.

Liu Y, Su Q, Li L . Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials. Clin Cardiol. 2013; 36(12):E41-8. PMC: 6649596. DOI: 10.1002/clc.22198. View

14.

Garcia-Mendez R, Almeida-Gutierrez E, Serrano-Cuevas L, Sanchez-Diaz J, Rosas-Peralta M, Ortega-Ramirez J . Reduction of No Reflow with a Loading Dose of Atorvastatin before Primary Angioplasty in Patients with Acute ST Myocardial Infarction. Arch Med Res. 2018; 49(8):620-629. DOI: 10.1016/j.arcmed.2018.10.006. View

15.

Li W, Fu X, Wang Y, Li X, Yang Z, Wang X . Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012; 122(3):195-202. DOI: 10.1159/000339472. View

16.

Levine G, Bates E, Bittl J, Brindis R, Fihn S, Fleisher L . 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update.... Circulation. 2016; 134(10):e123-55. DOI: 10.1161/CIR.0000000000000404. View

17.

Mustafa R, Santesso N, Brozek J, Akl E, Walter S, Norman G . The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. J Clin Epidemiol. 2013; 66(7):736-42. DOI: 10.1016/j.jclinepi.2013.02.004. View

18.

McGinn T, Wyer P, Newman T, Keitz S, Leipzig R, For G . Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ. 2004; 171(11):1369-73. PMC: 527344. DOI: 10.1503/cmaj.1031981. View

19.

Hahn J, Kim H, Choi Y, Jo S, Kim H, Lee S . Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2011; 162(6):1026-33. DOI: 10.1016/j.ahj.2011.08.011. View

20.

Gavazzoni M, Gorga E, Derosa G, Maffioli P, Metra M, Raddino R . High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. Drug Des Devel Ther. 2017; 11:3425-3434. PMC: 5720039. DOI: 10.2147/DDDT.S135173. View